Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin.

Slides:

Advertisements

Similar presentations

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Advertisements

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Combination therapy for adult T-cell leukemia–xenografted mice: flavopiridol and anti-CD25 monoclonal antibody by Meili Zhang, Zhuo Zhang, Carolyn K. Goldman,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study by Yu Wang, Qi-Fa Liu, Lan-Ping Xu, Kai-Yan Liu,

by Sandra Luna-Fineman, Kevin M. Shannon, Susan K

The effect of variation in donor platelet function on transfusion outcome: a semirandomized controlled trial by Anne M. Kelly, Stephen F. Garner, Theodora.

One giant leap for pediatric AMKL

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia by Charles Koller,

by Wolfram Springer, Alexander von Ruecker, and Roswitha Dickerhoff

Protease inhibitors potentiate chemotherapy-induced neutropenia

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation Aaron Gerds, Mary Fox-Geiman,

Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes (“pre-ATL”) in a 20-year follow-up study by Yoshitaka Imaizumi, Masako.

David F. Katz et al. JACEP 2016;j.jacep

The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar,

Multimorbidity and risk among patients with established cardiovascular disease: a cohort study by Liam G Glynn, Brian Buckley, Donal Reddan, John Newell,

Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions by Priyanka Pandey, Waseem Q. Anani,

Overall survival by SCT versus observation in first complete remission

Single umbilical cord blood with or without CD34+ cells from a third-party donor in adults with leukemia by Jaime Sanz, Mi Kwon, Guiomar Bautista, Miguel.

Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA- Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses.

David F. Katz et al. JACEP 2017;3:20-28

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

by Geling Li, Emily Waite, and Julie Wolfson

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib by Cecelia R. Miller, Amy S. Ruppert,

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure by Justine E. Marum, David T. Yeung,

Volume 2(Supplement 1):46-49

Ontogeny of platelet function

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry by Donald M. Arnold, Ishac Nazy, Rumi.

by David Deambrosis, Su Han Lum, Ryan M

by Matthew S. Painschab, Kate D

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Impact of age on clinical risk scores in follicular lymphoma

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation by Roni Shouval, Joshua A. Fein,

Balancing bleeding in brain metastases

Cold agglutinin disease

Outcomes in patients with PTCL

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Presentation transcript:

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial by Jessica C. Cardenas, Xu Zhang, Erin E. Fox, Bryan A. Cotton, John R. Hess, Martin A. Schreiber, Charles E. Wade, and John B. Holcomb BloodAdv Volume 2(14):1696-1704 July 24, 2018 © 2018 by The American Society of Hematology

Jessica C. Cardenas et al. Blood Adv 2018;2:1696-1704 © 2018 by The American Society of Hematology

Kaplan-Meier curves. Kaplan-Meier curves. Curves demonstrate cumulative incidence of death during the first 6 hours (A) and 30 days (B). Jessica C. Cardenas et al. Blood Adv 2018;2:1696-1704 © 2018 by The American Society of Hematology

Platelet counts over time. Platelet counts over time. Counts (per microliter) measured by flow cytometric analysis (CD42b+ cells) over time among only those patients who did not receive prerandomized blood products before the 0-hour blood draw. Data are presented as box and whiskers plots. Jessica C. Cardenas et al. Blood Adv 2018;2:1696-1704 © 2018 by The American Society of Hematology